Horizon Kinetics Medical ETF (MEDX): Assessing the Path to a $43 Target

Key Takeaways

• The $43 target is not an analyst consensus on the ETF itself but a publicly available 12-month price objective derived from the weighted average analyst price targets on MEDX's underlying holdings.
• TipRanks' ETF forecast, built from targets on the fund's 31 holdings, shows an average of about $43.29, with a range of roughly $32.45 to $52.67.
• At a recent price near $36, reaching $43 would require upside of roughly 19–20%, a substantial move for a diversified healthcare fund.
• The portfolio is 100% healthcare, with heavy weight in large-cap pharmaceuticals such as Eli Lilly, AbbVie, Novartis, and Johnson & Johnson.
• The strongest supporting factors are the long-term growth of global drug spending and exposure to high-margin branded pharmaceuticals.
• The biggest risks are concentration in a few large holdings, the fund's small AUM, and regulatory or pipeline setbacks in healthcare.
• For more detail on the fund's Major News and Today's Price Move, its Forecast, and Earnings of key holdings, explore these dedicated pages.

How the $43 Target Came About

Because MEDX is an ETF, there is no direct stock price target published by sell-side analysts on the fund itself. Instead, the $43 figure reflects public discussion and third-party research that converts analyst price targets on the fund's holdings into an implied fund-level objective. TipRanks publishes an ETF forecast for MEDX that aggregates 12-month price targets on the 31 stocks it holds, producing an average of about $43.29, with a low near $32.45 and a high near $52.67. This derived figure is a weighted reflection of Wall Street's views on large holdings such as Eli Lilly (LLY) and AbbVie (ABBV), not a formal consensus rating on MEDX. Rounded for readability, this gives a central target of $43. I also checked this using Tickeron’s AI Screener to see how the holdings stack up against peers.

Current Market Position and Path Toward the Target

MEDX has recently traded in the mid-$30s, near $36, with a 52-week range spanning roughly $29 to $37.90. Reaching $43 from that level would require an advance of about 19–20%, which qualifies as a substantial move. The fund's largest positions — including Eli Lilly at nearly 20% of assets, AbbVie at roughly 10%, and Novartis (NVS) and Johnson & Johnson (JNJ) at roughly 6% each — mean the path toward $43 depends heavily on sustained strength in branded pharmaceuticals. Additional positions in Amgen (AMGN), Merck (MRK), Bristol-Myers Squibb (BMY), and Pfizer (PFE) broaden the exposure but keep the fund firmly tied to the healthcare sector's fortunes.

What Could Support a Move Toward the Target

Several factors could support upside. Global healthcare spending is widely projected to keep rising over the long term, favoring companies with patented, high-margin drugs. MEDX's managers emphasize first-line pharmaceuticals and biologics with strong barriers to entry, a style that benefits from durable pricing power and pipeline innovation. Continued strength in obesity, oncology, and immunology franchises — areas where Eli Lilly, AbbVie, and others hold leading positions — could lift the fund's net asset value. A rotation back toward defensive, cash-generative healthcare names during periods of macroeconomic uncertainty could also provide a tailwind, as could favorable interest-rate conditions that reduce the appeal of fixed income relative to dividend-paying healthcare equities.

What Could Prevent the Target From Being Reached

Concentration is the clearest structural risk. With Eli Lilly alone representing roughly a fifth of assets, a single-stock setback could weigh materially on the fund. Regulatory developments, drug-pricing reform, patent expirations, and clinical-trial failures can compress valuations across the sector. The fund's modest AUM of roughly $17 million and thin average daily trading volume can also produce wider bid-ask spreads and make the fund less liquid than larger healthcare ETFs. Finally, a broader shift in investor preference toward growth sectors such as technology, or a sell-off in defensive names, could leave MEDX trading below its recent highs for an extended period.

Technical Levels and Market Structure

On a technical basis, the fund's 52-week high near $37.90 represents an important resistance level; a decisive move above that zone would be a necessary first step before the $43 objective comes into focus. The low-to-mid-$30s — around the fund's 52-week low of roughly $29 and the more recent support near $30.79 — marks a key area where buyers have previously stepped in. A round-number level such as $40 could also act as a psychological hurdle. The fund remains in a broad uptrend over the past year, but its path toward the target depends on holding above these support zones while clearing prior highs.

Time Horizon and What Investors Should Monitor

The $43 objective reflects a roughly 12-month research horizon, matching the typical window of the underlying analyst price targets used to derive it. Investors should watch quarterly earnings and pipeline news from the fund's largest holdings — particularly Eli Lilly and AbbVie — along with broader healthcare policy developments and drug-pricing legislation. Interest-rate decisions from the FOMC and sector fund flows can also influence how healthcare equities are valued. Any material change in analyst targets on major holdings would directly shift the implied fund-level objective, so monitoring revisions is essential.

Using AI Daily Buy/Sell Signals in Practice

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For an instrument like MEDX, where much of the story is driven by underlying holdings and sector momentum, these automated signals can help traders spot changing trends more efficiently, monitor positions, and surface new opportunities without manually scanning hundreds of charts. I find them useful as one input alongside fundamental review when evaluating healthcare exposure.

Final Assessment

The $43 target for MEDX is a substantial objective requiring roughly 19–20% upside from recent levels near $36. It is grounded in the weighted analyst price targets on the fund's underlying holdings rather than in a consensus rating on the ETF itself, with an implied range spanning from the low $30s to the low $50s that reflects genuine disagreement about the healthcare sector's near-term direction. Support could come from durable pharmaceutical demand and strength in key franchises, while concentration, regulatory risk, and limited liquidity represent the principal obstacles. Whether MEDX approaches $43 will ultimately depend on how its largest holdings perform and whether healthcare equities attract renewed investor interest, and no outcome should be treated as guaranteed.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume